Medical-Grade Titanium Patents: Leaders, Trends & White Space 2026
- Filing has cooled since its 2017 peak. 751 records that year against 519 at the 2022 midpoint and 77 in the most recent (partial) year — publication lag means the latest year always understates true filing activity.
- No single filer controls the field. The leader holds 387 records and the ranked top 5 combine for just 7.0% of all 19,666 records in scope — this is a fragmented landscape, not a walled garden.
- Coating and surface chemistry dominate the claim space. C23C coating and surface deposition alone touches 19.1% of records, well ahead of alloy composition (C22C) and sterilising/disinfecting (A61L) classes.
What this landscape covers
This dataset tracks 19,666 published patent records filed between 2015 and mid-2026 that combine titanium or implant-grade titanium alloy claims with fatigue strength, notch sensitivity, surface treatment, beta-titanium composition, MRI compatibility, traceability or material certification language. The scope spans structural and biomedical use, which is why coating chemistry and alloy metallurgy classes sit alongside sterilising and disinfecting codes in the same corpus.
Titanium's appeal for implants and structural medical hardware rests on a narrow set of trade-offs: fatigue life under cyclic loading, corrosion resistance, and compatibility with imaging equipment. Patent activity in this space therefore clusters around three levers — bulk alloy composition, surface treatment or coating, and post-processing heat treatment — rather than around a single dominant chemistry.
Filing trends and technology composition
Two views of the same 19,666-record corpus: the year-by-year filing curve, and how records distribute across IPC subclasses. Because a single record can carry several IPC codes, the class shares below add up to more than the record total — read each as its own share of all records, not as a slice of a whole.
Filing peaked in 2017 and has not returned
Filings ran at 751 in 2017, held roughly steady through 519 at the 2022 midpoint, and stand at 77 in the most recent, still-partial year. Publication typically lags filing by around 18 months, so the last one to two years will always look thinner than they eventually turn out to be — but the multi-year decline from the 2017 peak predates that lag effect.
Coating and surface chemistry lead, sterilisation trails
C23C (coating and surface deposition) covers 19.1% of records, followed by C22C (alloys) at 13.9% and C09D (coatings, paints and inks) at 11.0%. A61L, the sterilising and disinfecting class most specific to medical device handling, sits at 6.5% — a reminder that most of this corpus is written from a materials-science angle rather than a clinical-device angle.
Shares are the percentage of the 19,666 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Medical-Grade Titanium Materials with Eureka
This page is one run against one query. Ask Eureka your own question about medical-grade titanium materials and every answer comes back with the patent numbers behind it.
Try EurekaA foundational claim on fatigue strength and ductility
Titanium alloy having high ductility, fatigue strength and rigidity and method of manufacturing same
A titanium alloy is provided wherein metal boride is uniformly crystallized and/or precipitated in the matrix. The heating temperature in the finishing hot working is set smaller than the beta transus temperature by not less than 10°C, causing the matrix to include an equiaxial alpha structure at a rate of not less than 40 vol%. This gives the alloy high rigidity, ductility and fatigue strength suited to structural components across automotive, aerospace and rail applications.Filed by Sumitomo Metal Industries; published 2003-05-08 as US20030084970A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5888201A | Titanium alloy self-expanding stent | 832 |
| 2 | US5009675A | Coated silicon carbide abrasive grain | 621 |
| 3 | US4920954A | Ultrasonic device for applying cavitation forces | 536 |
| 4 | US6189482B1 | High temperature, high flow rate chemical vapor deposition apparatus and related methods | 451 |
| 5 | US20130288427A1 | Methods Of Fabricating Dielectric Films From Metal Amidinate Precursors | 429 |
| 6 | US5549607A | Apparatus for spinal fixation system | 404 |
| 7 | US5370195A | Drill bit inserts enhanced with polycrystalline diamond | 403 |
| 8 | US6555901B1 | Semiconductor device including eutectic bonding portion and method for manufacturing the same | 389 |
| 9 | US6254550B1 | Preformed wire guide | 375 |
| 10 | US5628787A | Clad composite stent | 366 |
Citation counts favour older, earlier-filed records in a searched corpus — treat them as a marker of influence on later filings, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data tells you
Three patterns worth acting on before drafting claims or scoping freedom-to-operate in this space.
Fragmented at the top
The leading assignee holds 387 records and fifth place holds 227, yet the top 5 together account for only 7.0% of all 19,666 records in scope. No single company has cornered fatigue-strength or surface-treatment claims; the field rewards a targeted freedom-to-operate search over a single-competitor watch.
Activity has cooled from its 2017 high
Filings ran at 751 in the peak year, held near 519 by the 2022 midpoint, and have fallen to 77 in the latest partial year. Several previously active filers show zero filings in the latest year tracked, though the recency of the cut-off means some of that drop reflects publication lag rather than a real stop in R&D.
US and Europe lead filing venues
The United States receives the most filings at 4,548, ahead of the EPO at 3,247, China at 2,928 and Japan at 2,676. WIPO/PCT filings (931) and Canada (686) trail well behind, suggesting most applicants still prioritise direct national or regional filing over PCT routing for this technology.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to medical-grade titanium materials, with the prior art for and against each one.
The competitive set
The ranked assignee list covers 100 companies — the full list the data endpoint returns, not a curated top tier. Reading it alongside the momentum data shows a field where legacy steel, chemical and industrial-gas companies still hold the largest single blocks, but recent-year activity from several of them has dropped to zero.
One steel and materials major leads by volume
The top-ranked assignee's 387 records outpace the rest of the field, but that lead sits within a ranking of 100 companies where the next several places (down to 227 at fifth) are close enough that no single company defines the field's direction.
Most activity sits outside the ranked leaders
The ranked top 10 together account for 12.3% of all records in scope, meaning the large majority of filings come from assignees outside that group. This is consistent with a technology area built on incremental process and coating improvements rather than one or two blocking platforms.
Co-filing is limited and mostly bilateral
Only 10 co-assignee pairs appear in the data, the strongest linking a steel producer with a coatings company. That pattern points to joint filings between materials suppliers and surface-treatment specialists rather than broad multi-party consortia.
| Assignee | Recent year | YoY |
|---|---|---|
| Nippon Steel Corporation | 0 | — |
| E.I. du Pont de Nemours & Co. | 0 | — |
| Nihon Parkerizing Co., Ltd. | 0 | -100% |
| Canon Inc. | 0 | -100% |
| Nippon Paint Co., Ltd. | 0 | — |
| General Electric Company | 0 | -100% |
| JFE Steel Corporation | 0 | — |
| Resonac Holdings Corporation | 0 | — |
Where to take this
The trend and ranking data point to specific next steps depending on whether you are scoping freedom-to-operate or looking for open claim space.
Run a targeted FTO search
With no single assignee controlling more than a small share of records, freedom-to-operate work should map claims by sub-technology (coating chemistry, alloy composition, heat treatment) rather than by a short list of competitors.
Explore assignee data in Eureka →Watch the momentum shift
Several previously active filers show zero filings in the latest tracked year. Confirm whether that reflects publication lag or an actual pullback before deciding whether a space is truly quiet.
Track filing momentum in Eureka →Test the under-claimed branches
MRI compatibility and traceability/certification language appear far less often than coating and alloy claims. A first claim drafted specifically around these could sit on lighter prior art.
Search white space in Eureka →Common questions on medical-grade titanium patents
The leading assignee in this dataset holds 387 records, with the fifth-ranked assignee at 227 and the tenth at 187. Together the top 5 account for only 7.0% of the 19,666 records in scope, so no single company dominates the space. A freedom-to-operate review should therefore look across the full ranked list of 100 companies rather than treating this as a two- or three-player field.
Filings peaked at 751 in 2017 and have declined since, sitting at 519 by the 2022 midpoint and 77 in the most recent, still-partial year. Some of that recent drop is an artefact of publication lag, which typically runs around 18 months, so the last year or two will always look thinner than it eventually proves to be. Even accounting for lag, the multi-year trend from 2017 onward points to a maturing rather than an accelerating filing pattern.
The largest single class is C23C, coating and surface deposition, covering 19.1% of the 19,666 records in scope. C22C (alloys) follows at 13.9%, then C09D (coatings, paints and inks) at 11.0%. Because records can carry multiple IPC codes, these percentages overlap rather than sum to 100%, but the ordering shows surface treatment and coating chemistry drawing more filing activity than bulk alloy composition alone.
US20030084970A1, assigned to Sumitomo Metal Industries and published in 2003, claims a titanium alloy with metal boride precipitated in the matrix and a specific heat-treatment window relative to the beta transus temperature that produces a defined equiaxial alpha structure. Anyone drafting claims around fatigue strength achieved through boride precipitation and controlled hot-working temperature near beta transus should check this record closely, since it predates most of the corpus and has drawn substantial citation. Designing around it typically means either a different strengthening mechanism or a materially different heat-treatment window.
Classes tied specifically to clinical use, such as A61L (sterilising and disinfecting) at 6.5% of records, and specialised branches like MRI compatibility, traceability marking and material certification, show noticeably lower filing density than the core coating and alloy classes. That gap does not mean the technology is unsolved, but it does mean fewer blocking claims sit directly on those combinations. A first claim written specifically around MRI-compatible surface treatment or certification-linked traceability marking is more likely to clear a novelty search than one written around general coating chemistry.
Research Medical-Grade Titanium Materials in depth with Eureka
Go past this page: query the whole medical-grade titanium materials corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.